IL133303A0 - Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft - Google Patents
Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graftInfo
- Publication number
- IL133303A0 IL133303A0 IL13330398A IL13330398A IL133303A0 IL 133303 A0 IL133303 A0 IL 133303A0 IL 13330398 A IL13330398 A IL 13330398A IL 13330398 A IL13330398 A IL 13330398A IL 133303 A0 IL133303 A0 IL 133303A0
- Authority
- IL
- Israel
- Prior art keywords
- insulin
- producing tissue
- graft
- compositions
- tissue graft
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 230000007547 defect Effects 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Steroid Compounds (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5026797P | 1997-06-20 | 1997-06-20 | |
| US7726598P | 1998-03-09 | 1998-03-09 | |
| PCT/US1998/012892 WO1998058669A2 (en) | 1997-06-20 | 1998-06-19 | Cd154 blockade therapy for pancreatic islet tissue transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL133303A0 true IL133303A0 (en) | 2001-04-30 |
Family
ID=26728084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13330398A IL133303A0 (en) | 1997-06-20 | 1998-06-19 | Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20030072754A1 (enExample) |
| EP (1) | EP1051191B1 (enExample) |
| JP (1) | JP2002506446A (enExample) |
| KR (1) | KR100634847B1 (enExample) |
| CN (2) | CN1195546C (enExample) |
| AT (1) | ATE339966T1 (enExample) |
| AU (1) | AU730763B2 (enExample) |
| BG (1) | BG64976B1 (enExample) |
| BR (1) | BR9810620A (enExample) |
| CA (1) | CA2294154A1 (enExample) |
| DE (1) | DE69835965T2 (enExample) |
| EA (1) | EA002550B1 (enExample) |
| EE (1) | EE9900588A (enExample) |
| HU (1) | HUP0003160A3 (enExample) |
| IL (1) | IL133303A0 (enExample) |
| IS (1) | IS5273A (enExample) |
| NO (1) | NO996275L (enExample) |
| NZ (1) | NZ502052A (enExample) |
| SK (1) | SK180299A3 (enExample) |
| TR (1) | TR199903142T2 (enExample) |
| WO (1) | WO1998058669A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999045958A1 (en) * | 1998-03-09 | 1999-09-16 | Biogen, Inc. | Cd154 blockade therapy for modulation of immune responses to implanted devices |
| AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| AU2001275186A1 (en) * | 2000-06-02 | 2001-12-17 | Nicole Kirchhof | Immunotherapeutic method to prevent islet cell rejection |
| IL152316A0 (en) * | 2000-06-09 | 2003-05-29 | Bristol Myers Squibb Co | Pharmaceutical compositions and kits for treating transplant rejection |
| JP4667383B2 (ja) * | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用 |
| EA014226B1 (ru) | 2004-07-26 | 2010-10-29 | Байоджен Айдек Ма Инк. | Антитела к cd154, их фрагменты и способы применения антител и фрагментов |
| JP2008520235A (ja) * | 2004-11-22 | 2008-06-19 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | インスリンを産生可能な拡大され、かつ再分化した成体島β細胞の集団およびその作製方法 |
| WO2007047539A2 (en) * | 2005-10-14 | 2007-04-26 | Medtronic, Inc. | Localized delivery to the lymphatic system |
| US8636995B2 (en) | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
| US8372399B2 (en) | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
| US8911739B2 (en) | 2009-02-10 | 2014-12-16 | Trustees Of Columbia University In The City Of New York | Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide |
| US9527912B2 (en) | 2010-05-17 | 2016-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US10147463B2 (en) | 2014-12-10 | 2018-12-04 | Nxp Usa, Inc. | Video processing unit and method of buffering a source video stream |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| KR101810778B1 (ko) * | 2015-06-23 | 2017-12-20 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
| US10986309B2 (en) | 2015-06-30 | 2021-04-20 | Nxp Usa, Inc. | Video buffering and frame rate doubling device and method |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5227298A (en) * | 1990-08-17 | 1993-07-13 | The Trustees Of Columbia University In The City Of New York | Method for microencapuslation of cells or tissue |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| JP4751493B2 (ja) * | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
-
1998
- 1998-06-19 KR KR1019997011991A patent/KR100634847B1/ko not_active Expired - Fee Related
- 1998-06-19 WO PCT/US1998/012892 patent/WO1998058669A2/en not_active Ceased
- 1998-06-19 AU AU79830/98A patent/AU730763B2/en not_active Ceased
- 1998-06-19 NZ NZ502052A patent/NZ502052A/xx unknown
- 1998-06-19 DE DE69835965T patent/DE69835965T2/de not_active Expired - Fee Related
- 1998-06-19 JP JP50490799A patent/JP2002506446A/ja not_active Ceased
- 1998-06-19 CA CA002294154A patent/CA2294154A1/en not_active Abandoned
- 1998-06-19 SK SK1802-99A patent/SK180299A3/sk unknown
- 1998-06-19 HU HU0003160A patent/HUP0003160A3/hu unknown
- 1998-06-19 BR BR9810620-1A patent/BR9810620A/pt not_active Application Discontinuation
- 1998-06-19 EP EP98930436A patent/EP1051191B1/en not_active Expired - Lifetime
- 1998-06-19 TR TR1999/03142T patent/TR199903142T2/xx unknown
- 1998-06-19 AT AT98930436T patent/ATE339966T1/de not_active IP Right Cessation
- 1998-06-19 CN CNB988064413A patent/CN1195546C/zh not_active Expired - Fee Related
- 1998-06-19 IL IL13330398A patent/IL133303A0/xx unknown
- 1998-06-19 CN CNA2005100079419A patent/CN1651919A/zh active Pending
- 1998-06-19 EE EEP199900588A patent/EE9900588A/xx unknown
- 1998-06-19 EA EA200000058A patent/EA002550B1/ru not_active IP Right Cessation
-
1999
- 1999-11-26 IS IS5273A patent/IS5273A/is unknown
- 1999-12-17 NO NO996275A patent/NO996275L/no unknown
-
2000
- 2000-01-18 BG BG104091A patent/BG64976B1/bg unknown
-
2002
- 2002-10-11 US US10/270,783 patent/US20030072754A1/en not_active Abandoned
-
2006
- 2006-12-13 US US11/638,244 patent/US20070292440A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR9810620A (pt) | 2000-10-03 |
| HK1033548A1 (en) | 2001-09-07 |
| EA200000058A1 (ru) | 2000-08-28 |
| BG104091A (en) | 2000-10-31 |
| EP1051191B1 (en) | 2006-09-20 |
| CN1261286A (zh) | 2000-07-26 |
| EP1051191A2 (en) | 2000-11-15 |
| IS5273A (is) | 1999-11-26 |
| WO1998058669A3 (en) | 1999-04-29 |
| CN1651919A (zh) | 2005-08-10 |
| TR199903142T2 (xx) | 2000-09-21 |
| EA002550B1 (ru) | 2002-06-27 |
| SK180299A3 (en) | 2000-06-12 |
| HUP0003160A3 (en) | 2002-09-30 |
| NO996275D0 (no) | 1999-12-17 |
| JP2002506446A (ja) | 2002-02-26 |
| WO1998058669A2 (en) | 1998-12-30 |
| US20030072754A1 (en) | 2003-04-17 |
| CA2294154A1 (en) | 1998-12-30 |
| ATE339966T1 (de) | 2006-10-15 |
| KR100634847B1 (ko) | 2006-10-17 |
| NO996275L (no) | 2000-02-21 |
| CN1195546C (zh) | 2005-04-06 |
| EE9900588A (et) | 2000-08-15 |
| KR20010013965A (ko) | 2001-02-26 |
| US20070292440A1 (en) | 2007-12-20 |
| AU7983098A (en) | 1999-01-04 |
| DE69835965D1 (de) | 2006-11-02 |
| NZ502052A (en) | 2001-01-26 |
| BG64976B1 (bg) | 2006-11-30 |
| AU730763B2 (en) | 2001-03-15 |
| HUP0003160A2 (hu) | 2001-01-29 |
| DE69835965T2 (de) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL133303A0 (en) | Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft | |
| CA2320040A1 (en) | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation | |
| AU655915B2 (en) | Cosmetic deodorants | |
| HUP0003392A2 (hu) | CD40:CD154 Kötés megszakításának alkalmazása beépülés elleni immunválaszok, különösen graft-kilökődés megakadályozására | |
| CA2312936A1 (en) | Compositions and methods for weight reduction | |
| ZA9510295B (en) | Novel dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals | |
| Turcotte et al. | Mechanisms of action of Mycobacterium bovis BCG-induced suppressor cells in mitogen-induced blastogenesis | |
| WO2003102162A3 (en) | Novel tolerogenic dendritic cells and therapeutic uses therefor | |
| HUT67008A (en) | Preparation containing gamma interferon for the treatment of infections in transplant recipients | |
| IL95046A0 (en) | Substituted 2-imidazolines and pharmaceutical compositions containing them | |
| IL131478A0 (en) | Methods for treatment of scar tissue | |
| EP1754490A3 (en) | CD 154 blockage therapy for pancreatic islet tissue transplantation in primates | |
| MXPA03010921A (es) | Uso de acetil l-carnitina en asociacion con biotina para tratamiento der pacientes con diabetes mellitus resistente a insulina tipo 2. | |
| EP0886528A4 (en) | USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASES | |
| AU6953296A (en) | Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation | |
| HRP930833B1 (en) | Water soluble retinoids | |
| DE69231583D1 (de) | Zusammensetzung zur Behandlung des Insulinmangels bei Säugetieren, die Amylin und Insulin enthält. | |
| BE900089A (fr) | Utilisation de mini-somatostatines en therapeutique. | |
| IL98852A0 (en) | Process for the preparation of sulphinylpristinamycin iib | |
| PL309339A1 (en) | Novel triazoquinazolines, methods of obtaining them and their application | |
| JPS5765181A (en) | Heat-resistant adenylate kinase and its preparation | |
| IL117734A (en) | Anellated beta-carbolines their preparation and pharmaceutical compositions containing them | |
| UA36081A (uk) | Спосіб корекції дисмікроелементемії |